文献速递淋巴瘤

泽布替尼治疗复发/难治性边缘区淋巴瘤的安全性与疗效:MAGNOLIA研究最终分析

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
PubMed 文献 · Blood Adv · 2023-01-01

MAGNOLIA是一项开放标签、单臂、多中心2期研究,纳入68例既往接受过至少1种抗CD20方案的复发/难治性边缘区淋巴瘤患者,评估泽布替尼160 mg每日两次的疗效与安全性。中位随访27.4个月,独立评审委员会评估的客观缓解率为68.2%,24个月缓解持续时间无事件率72.9%,24个月无进展生存率和总生存率分别为70.9%和85.9%,未观察到新的安全性信号。

要点

  • 泽布替尼160 mg每日两次在复发/难治性边缘区淋巴瘤中IRC评估ORR为68.2%。
  • 中位随访27.4个月,24个月DOR无事件率72.9%,PFS率70.9%,OS率85.9%。
  • 安全性特征与主要分析一致,未观察到新的安全性信号。

核心结论

  • 泽布替尼在复发/难治性边缘区淋巴瘤中展现出持续超过2年的临床缓解,73%的缓解者在最终分析时仍存活且无进展。
  • 随着治疗时间延长,泽布替尼继续表现出良好的安全性/耐受性特征。

研究设计与样本

  • MAGNOLIA为开放标签、单臂、多中心2期研究,最终分析旨在描述缓解持久性及更长期安全性和耐受性。
  • 研究纳入68例复发/难治性边缘区淋巴瘤患者,既往接受过至少1种抗CD20方案,接受泽布替尼160 mg每日两次治疗。
  • 主要终点为独立评审委员会评估的客观缓解率,次要终点包括研究者评估的客观缓解率、缓解持续时间、无进展生存、总生存、健康相关生活质量、安全性和耐受性。
  • 试验注册号为NCT03846427。

主要发现

  • 中位随访27.4个月,独立评审委员会评估的客观缓解率为68.2%(95%CI 55.6-79.1)。
  • 24个月缓解持续时间无事件率为72.9%(95%CI 54.4-84.9)。
  • 24个月无进展生存率为70.9%(95%CI 57.2-81.0),24个月总生存率为85.9%(95%CI 74.7-92.4)。
  • 安全性特征与主要分析一致,未观察到新的安全性信号;房颤/房扑发生2例(2.9%),高血压3例(4.4%)。
  • 中性粒细胞减少是最常见的≥3级不良事件,发生8例(11.8%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), with a favorable safety/tolerability profile. Presented here, is the final analysis of MAGNOLIA, performed to characterize the durability of response and longer-term safety and tolerability. Zanubrutinib (160 mg twice daily) was evaluated in 68 patients with R/R MZL who had received at least 1 anti-CD20-directed regimen. The primary end point was independent review committee (IRC)-assessed ORR. Secondary end points included investigator-assessed ORR, duration of response (DOR), progression-free survival (PFS), overall survival (OS), health-related quality of life, safety, and tolerability. With a median follow-up of 27.4 months, the IRC-assessed ORR was 68.2% (95% confidence interval [CI], 55.6-79.1), with a 24-month DOR event-free rate of 72.9% (95% CI, 54.4-84.9). PFS and OS at 24 months were 70.9% (95% CI, 57.2-81.0) and 85.9% (95% CI, 74.7-92.4), respectively. The zanubrutinib safety profile was consistent with the primary analysis, with no new safety signals observed. Atrial fibrillation/flutter (n = 2 [2.9%]) and hypertension (n = 3 [4.4%]) were uncommon. Neutropenia (n = 8 [11.8%]) was the most common grade ≥3 adverse event. In this final analysis of MAGNOLIA, zanubrutinib demonstrated sustained clinical responses beyond 2 years, with 73% of responders alive and progression free. Zanubrutinib continued to demonstrate a favorable safety/tolerability profile with the additional time on treatment. This trial was registered at www.clinicaltrials.gov as #NCT03846427.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Opat S, Tedeschi A, Hu B, et al. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv. 2023. PMID: 37682792. doi:10.1182/bloodadvances.2023010668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。